PhD Thesis

About me/PhD thesis
Defended · 25 May 2022

Glucose control therapies in the perioperative period

My PhD thesis, defended at the University of Amsterdam, covering two lines of work: how diabetes is managed around the time of surgery, and whether GLP-1 receptor agonists can safely replace insulin for perioperative glucose control — the research that became the GLOBE trial.

Defended25 May 2022Agnietenkapel, University of Amsterdam, 16:00
DegreePhDFaculty of Medicine, Universiteit van Amsterdam
ISBN978-94-6419-497-5

Funding. Novo Nordisk provided funding through its Investigator Initiated Study programme for the studies making up Chapters 5, 6 and 7 — the GLOBE trial protocol, its main results, and the cardiac substudy. No other funding sources applied to the contents of this thesis.

Summary

The thesis is in two parts. Part I looks at how patients with diabetes are actually managed around surgery: a nationwide survey found treatment goals and insulin dosing varied widely between Dutch hospitals, patients with type 1 diabetes had worse glucose control than those with type 2 despite identical protocols, and — in a randomised trial — continuing metformin through the perioperative period didn’t improve glucose control over withholding it, though it also didn’t raise lactate to a concerning degree.

Part II turns to GLP-1 receptor agonists as an alternative to insulin. A systematic review of incretin-based therapy in perioperative and intensive care found it lowered glucose and reduced insulin use without more hypoglycaemia. That groundwork led to the GLOBE trial: a multicentre, placebo-controlled study of preoperative liraglutide in cardiac surgery patients. The main result confirmed the hypothesis — liraglutide reduced the need for intraoperative insulin and improved glycaemic control throughout, with no difference in complication rates. A secondary analysis found a higher rate of normal postoperative left-ventricular function in the liraglutide group, a hypothesis-generating signal for cardioprotection worth testing further. The closing chapter discusses the newer once-weekly GLP-1 formulations and argues, on balance, for continuing them perioperatively in patients already on them.

The concluding chapter argues that the next step is a larger, complication-powered trial — the line of work that continues through the Rubicon fellowship, the Marie Skłodowska-Curie ELECTRIC fellowship, and the MERCURI programme.

Committee & supervisors

prof. dr. B. Preckel

Promotor · Amsterdam UMC, University of Amsterdam

prof. dr. M.W. Hollmann

Promotor · Amsterdam UMC, University of Amsterdam

prof. dr. J.H. de Vries

Copromotor · Amsterdam UMC, University of Amsterdam

dr. J. Hermanides

Copromotor · Amsterdam UMC, University of Amsterdam

prof. dr. W.S. Schlack

Committee · Amsterdam UMC, University of Amsterdam

prof. dr. R.J.M. Klautz

Committee · Amsterdam UMC, University of Amsterdam

prof. dr. O.R.C. Busch

Committee · Amsterdam UMC, University of Amsterdam

prof. dr. N.P. Juffermans

Committee · Amsterdam UMC, University of Amsterdam

prof. dr. B.J.M. van der Meer

Committee · Tilburg University

dr. D.H. van Raalte

Committee · VU medisch centrum

Publications included in this thesis

Same layout as the full publications page — title, authors, then journal and year linking to the open-access version or DOI where available.

  • Peri-operative management of patients with diabetes mellitus in Dutch hospitals, a nation-wide survey of protocols
    Hulst AH, Hermanides J, Hollmann MW, DeVries JH, Preckel B.
    Ned Tijdschr Anesthesiol 2019
  • Lack of consensus on the peri-operative management of patients with diabetes mellitus
    Hulst AH, Hermanides J, Hollmann MW, DeVries JH, Preckel B.
  • Comparison of perioperative glucose regulation in patients with type 1 vs type 2 diabetes mellitus: A retrospective cross-sectional study
    Hulst AH, Polderman JAW, Kooij FO, Vittali D, Lirk P, Hollmann MW, DeVries JH, Preckel B, Hermanides J.
  • Perioperative continuation of metformin does not improve glycemic control in patients with type 2 diabetes; a randomized controlled trial
    Hulst AH, Polderman JAW, Ouweneel E, Pijl AJ, Hollmann MW, DeVries JH, Preckel B, Hermanides J.
  • In response to: Metformin for the management of peri-operative hyperglycaemia
    Hulst AH, Hermanides J, Hans DeVries J, Preckel B.
  • Preoperative Continuation of Oral Hypoglycemic Drugs
    Hulst AH, Preckel B, Hollmann MW, DeVries JH, Hermanides J.
  • Potential Benefits of Sodium-Glucose Cotransporter-2 Inhibitors in the Perioperative Period
    Hulst AH, Hermanides J, DeVries JH, Preckel B.
  • Systematic review of incretin therapy during peri-operative and intensive care
    Hulst AH, Plummer MP, Hollmann MW, DeVries JH, Preckel B, Deane AM, Hermanides J.
  • Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 for bridging of hyperglycaemia during cardiac surgery
    Hulst AH, Visscher MJ, Hermanides J, on behalf of the GLOBE study group.
  • Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial
    Hulst AH, Visscher MJ, Hermanides J, on behalf of the GLOBE study group.
  • Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial
    Hulst AH, Visscher MJ, Hermanides J, on behalf of the GLOBE study group.

Where this leads

The GLOBE trial and its findings are the starting point for the kidney-protection and glucose-regulation work described on the main research programme, and for the full record of everything published since.